X Biopharma Ltd. (SG:42C) has released an update. iX Biopharma Ltd. announced that its novel semaglutide sublingual wafer, iXB 401, achieved 20 ...

Glucagon-like peptide-1 (GLP-1) agonist are a family of medications that help manage blood sugar in patients with type 2 ...

There’s no hard-and-fast rule for how long it’s safe to stay on Ozempic for weight loss. Novo Nordisk-sponsored studies lasting up to two years show that semaglutide is safe.

Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

Dividing the drug candidates by condition type, 129.2 million could benefit from semaglutide for weight control, 35 million ...

As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.

Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor ...

The COVID pandemic set in motion trends with alcohol use that have persisted. Disruptions in work, school and lifestyle have ...

The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...

The FDA has approved a new drug called revumenib that can be taken orally to treat acute leukemia in patients 1 year or older. The drug will be marketed under the brand name Revuforj.

The FDA rejected an application from Astellas seeking to change the prescribing label for its eye drug Izervay to allow less ...